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ABSTRACT
Macrophages are important regulators of branching morphogenesis
during development and postnatally in the mammary gland.
Regulation of macrophage dynamics during these processes can
therefore have a profound impact on development. We demonstrate
here that the developing mammary gland expresses high levels of
inflammatory CC-chemokines, which are essential in vivo regulators
of macrophage migration. We further demonstrate that the atypical
chemokine receptor ACKR2, which scavenges inflammatory CC-
chemokines, is differentially expressed during mammary gland
development. We have previously shown that ACKR2 regulates
macrophage dynamics during lymphatic vessel development. Here,
we extend these observations to reveal a novel role for ACKR2 in
regulating the postnatal development of the mammary gland.
Specifically, we show that Ackr2−/− mice display precocious
mammary gland development. This is associated with increased
macrophage recruitment to the developing gland and increased
density of the ductal epithelial network. These data demonstrate
that ACKR2 is an important regulator of branching morphogenesis
in diverse biological contexts and provide the first evidence of a
role for chemokines and their receptors in postnatal development
processes.
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INTRODUCTION
During embryonic development, an epithelial placode forms in the
murine mammary gland mid-gestation (E11.5) and at birth a
rudimentary structure is present (Hens and Wysolmerski, 2005).
Most organs are patterned during embryogenesis or in the first week
after birth (Howlin et al., 2006; Wiseman and Werb, 2002).
However, the mammary gland is unique, as continual postnatal
development occurs throughout the female reproductive lifetime.
Ovarian hormones begin to be released at puberty (around 3 weeks)
and terminal end buds (TEBs) form at the distal tip of the epithelial
ducts. TEBs proliferate, grow invasively through the fat pad and
branch by bifurcation until the limit of the fat pad is reached and they
regress (Wiseman and Werb, 2002). During pregnancy, ductal
structures branch further and differentiate into lobuloalveoli to
produce milk during lactation. After weaning, involution occurs,
where 90% of the epithelium undergoes programmed cell death to
allow the gland to return to its pre-pregnancy state (Wiseman and
Werb, 2002).
The mammary gland fat pad comprises mainly fibroblasts, pre-
adipocytes, adipocytes and immune cells, and is separated from the
epithelial network by a periductal stroma of fibroblasts and
extracellular matrix (ECM) (Parmar and Cunha, 2004).
Macrophages, mast cells and eosinophils surround the growing
TEBs (Gouon-Evans et al., 2000; Lilla and Werb, 2010).
Macrophages are found in all tissues within the body and in
addition to mounting immune responses during inflammation, their
phagocytic and cytokine-producing properties are required for many
tissue remodelling processes during development. Colony stimulating
factor 1 (CSF1) is the main growth factor for macrophages, and Csf1-
deficient mice (Csfmop/Csfmop) are impaired in their ability to form
TEBs, show reduced ductal elongation and branching during puberty
(Gouon-Evans et al., 2000; Pollard and Hennighausen, 1994), and
have impaired development of lobuloalveoli in pregnancy.
Macrophages are found mainly around the neck or within the
TEBs, produce proteinases and growth factors, and promote collagen
fibrillogenesis (Gouon-Evans et al., 2000; Ingman et al., 2006).
Eosinophils and mast cells are also required for mammary gland
development, as CCL11-null and mast cell-deficient mice,
respectively, have impaired TEB and branch formation (Gouon-
Evans et al., 2000; Lilla and Werb, 2010).
Although the role of CCL11 in recruiting eosinophils to the
mammary gland has been well defined (Gouon-Evans et al., 2000),
there is limited evidence regarding the involvement of other
chemokines and their receptors in mammary gland development.
Chemokines are chemotactic cytokines that control cell migration
and have multiple functions in inflammation and homeostasis
(Griffith et al., 2014; Zlotnik and Yoshie, 2000), including the
regulation of macrophage dynamics during tissue remodelling.
ACKR2 is an example of a non-signalling, 7-transmembrane
spanning atypical chemokine receptor that lacks the DRYLAIV
motif characteristic of conventional chemokine receptors
(Bachelerie et al., 2014; Nibbs and Graham, 2013). ACKR2 is
expressed by lymphatic endothelial cells, by some leukocyte
populations, including B1 cells, and by stromal cells during
inflammation (Hansell et al., 2011; McKimmie et al., 2008; Nibbs
et al., 2001; Singh et al., 2012). ACKR2 is required for resolution of
the inflammatory response, by internalising CC-chemokines and
depositing them in the lysosome for degradation (Fra et al., 2003;
Weber et al., 2004). Exaggerated inflammation is seen at all sites of
normal ACKR2 expression in Ackr2−/− mice (Di Liberto et al.,
2008; Jamieson et al., 2005; Martinez de la Torre et al., 2007; Nibbs
et al., 2007).Received 13 May 2016; Accepted 7 November 2016
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Recently, we demonstrated that ACKR2 is an essential regulator
of dermal macrophage dynamics during embryonic branching
morphogenesis. Compared with wild-type mice, Ackr2−/− mice
have increased lymphatic vessel density that is associated with
altered recruitment and proximity of pro-lymphangiogenic
macrophages to developing lymphatic vessels at a range of tissue
sites (Lee et al., 2014). Here, we show that ACKR2 has a broader
role in the regulation of macrophage dynamics during branching
morphogenesis. We demonstrate strong expression of inflammatory
CC-chemokine ligands for ACKR2 during mammary gland
development and provide evidence that ACKR2 is expressed by
stromal fibroblasts in the developing mammary gland. Analysis of
developing mammary gland structures reveals that ACKR2
regulates epithelial branching by restricting levels of macrophage-
attracting chemokines. In Ackr2−/− mice, levels of these attractants
are elevated, leading to increased recruitment of macrophages and a
precocious mammary gland developmental phenotype. This study
therefore sheds important light on the regulation of macrophage
dynamics during mammary gland development and identifies
ACKR2 as a crucial player in this process. This study also provides
the first evidence of chemokine receptor involvement in postnatal
development.
RESULTS
Chemokines and their receptors are abundantly expressed
during mammary gland development
Using qRT-PCR-based arrays, we investigated the expression of
chemokines, their receptors and related molecules in the mammary
gland during development, pregnancy, lactation and involution.
Heat-map visualisation of the data is shown in Fig. 1, which reveals
markedly different patterns of chemokine and chemokine receptor
expression in the mammary gland in the four contexts studied.
Specifically, our data demonstrate that inflammatory CC-
chemokines (CCL2, CCL4-CCL9, CCL11, CCL17, CCL22 and
CCL26) and their receptors (CCR1, CCR2, CCR5) are strongly
expressed at different stages in the development of the mammary
gland in virgin mice (Fig. 1A). The strongest expression of the CC-
chemokines and their receptors was observed in mice aged between
6.5 and 12 weeks. The data also show that ACKR2 is expressed in
the developing mammary gland in mice aged between 6.5 and
8 weeks. In contrast to mammary gland development, inflammatory
CXC-chemokine activity is strongly apparent in the remodelling
mammary gland during pregnancy (Fig. 1B). Notably, there is
marked upregulation of CXCR1, CXCR2 and CXCR3 within
3 days of conception. In addition, the non-inflammatory CXC-
chemokine receptors CXCR4 and CXCR5 are also expressed at this
time point. Therefore CXC-chemokine activity typifies the early
stages of the mammary gland response to pregnancy. The
expression data from lactating and involuting mammary glands
revealed consistent patterns but these did not have the clear
chemokine-subfamily associations that are observed with
developing and pregnant mammary glands (Fig. 1C). Thus, these
data demonstrate strong expression of inflammatory CC-
chemokines and their scavenger receptor ACKR2 during
mammary gland development.
ACKR2 controls mammary gland branching morphogenesis
during development
Branching morphogenesis is an important process in the mammary
gland, generating the ductal epithelial network throughout postnatal
Fig. 1. Transcriptional regulation of chemokines and their receptors during mammary gland development. Heat-map representation of chemokine
transcript levels in the developing mammary gland showing markedly different patterns of chemokine and chemokine receptor expression. For ease of
interpretation, the data have been subdivided according to chemokine expression patterns common to (A) virgin development (n=3), (B) pregnancy (n=2), and
(C) lactation and involution (n=2).
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development (Macias and Hinck, 2012). Macrophages are known to
contribute to this process (Gouon-Evans et al., 2000; Wynn et al.,
2013), and their migration and dynamics in this context will be
regulated by a number of the inflammatory chemokines identified in
Fig. 1A. These chemokines are also ligands for ACKR2 and thus we
next determined whether ACKR2 contributes to the regulation of
branching morphogenesis in the mammary gland, as it does in
embryonic skin (Lee et al., 2014). Carmine Alum whole-mount
staining of the fourth inguinal mammary gland was carried out on
age- and weight-matched virgin wild-type and Ackr2−/− mice
(Fig. 2A). Defined developmental time points were chosen to
represent puberty (6 and 6.5 weeks) and adulthood (8 and
12 weeks), and at each time point mammary gland development
was quantified (Fig. 2B). At 6 weeks, ACKR2 deficiency does not
affect branching. However at 6.5 and 8 weeks old, Ackr2−/− mice
show accelerated development, as evidenced by an increased
number of branches (Fig. 2Ba) and size of the branched area
(Fig. 2Bb), and the reduced distance between branches (Fig. 2Bc).
In addition, there is an increased number of TEBs, the highly
proliferative structures that are responsible for generating the ductal
epithelial tree at their distal ends, suggesting enhanced proliferation
in pubertal and young adult Ackr2−/− mice (Fig. 2Bd). Finally,
Ackr2−/−mice displayed significantly increased ductal elongation at
8 weeks (Fig. 2Be). By 12 weeks TEBS have regressed, the ductal
tree has reached the end of the fat pad and ductal outgrowth is
completed, and at this stage there is no difference between wild-type
and Ackr2−/− animals (Fig. 2). ACKR2 does not affect the
morphology of individual TEBs or the thickness of epithelial
branches throughout development (Fig. S1A,B), nor were any
differences in inguinal lymph node size noted (Fig. S1C). Thus,
ACKR2 deletion is associated with accelerated mammary gland
development in late puberty.
ACKR2 is expressed by stromal cells in the mammary gland
ACKR2 expression was determined by qRT-PCR arrays and shown
to be expressed in the mammary gland at each of the developmental
stages investigated (Fig. 1A and Fig. 3A). Maximal expression of
ACKR2 in virgin mice was seen between weeks 6.5 and 8. More
modest expression was seen throughout pregnancy and during
lactation and involution. ACKR2 expression therefore coincides
with the time window in which we see accelerated mammary gland
development in the Ackr2−/− mice. To determine which resident
mammary gland cells express ACKR2, inguinal mammary gland
tissue was enzymatically digested from wild-type and Ackr2−/−
mice and analysed by flow cytometry for uptake of the fluorescently
labelled ACKR2 ligand CCL22 (Alexa-CCL22). There was no
difference in Alexa-CCL22 uptake by wild-type and Ackr2−/−
CD45+ cells, indicating that ACKR2 is not expressed by leukocytes
in the mammary gland (Fig. 3Ba). However, Alexa-CCL22 uptake
by CD45− cells was lower in Ackr2−/− animals (Fig. 3Bb).
Specifically, Alexa-CCL22 uptake was markedly reduced in a
population of fibroblastic cells (Singhal et al., 2016), which are
CD45− CD24− CD29+ Sca1+ CD90+, indicating that ACKR2 is
expressed by this stromal population (Fig. 3C,D). Pre-adipocytes
are an important component of the mammary stroma that are CD24−
CD29+ Sca1+ CD34+ (Berry and Rodeheffer, 2013); however, the
Fig. 2. ACKR2 controls branchingmorphogenesis during development. (A) Representative Carmine Alum whole mounts prepared from virgin wild-type and
Ackr2−/− mammary glands at 6 (n=6), 6.5 (n=8), 8 (n=8) and 12 weeks (n=9) are shown. Scale bars: 2 mm. (B) Branching morphogenesis was quantified by
measuring: (a) the number of branches where each data point represents the average from three individual fields of view (FOV) (5×) per gland; (b) the area of
branching from the inguinal lymph node using ImageJ; (c) the distance between branches where each data point represents the average from three
measurements taken from each of three individual FOV (5×) per gland. (d) The number of TEBs was determined as the average number from three FOV (5×).
(e) Ductal elongation was measured from the middle of the inguinal lymph node to the furthest edge of ductal outgrowth using ImageJ. Error bars represent s.e.m.
Significantly different results are indicated.
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Alexa-CCL22-binding cells are CD34− and do not belong to this
population. We next analysed the ability of the ACKR2 on these
cells to bind and/or internalise ligand. As shown in Fig. 3E, and
in keeping with the predominantly intracellular localisation of
ACKR2 (Blackburn et al., 2004), little ligand binding was detected
at 4°C, at which temperature ligand internalisation will be
minimal. By contrast, ACKR2-dependent internalisation of
ligand was seen at 37°C. Together, these data indicate that
ACKR2 is expressed on a stromal fibroblastic population in the
mammary gland and that, on these cells, it is capable of both
binding and internalising ligand.
ACKR2 regulates the levels of inflammatory CC-chemokines
in the mammary gland
One likely mechanism to explain the involvement of ACKR2 in
regulating mammary gland development relates to its ability to limit
inflammatory CC-chemokine levels in tissues. We therefore used
multiplexing approaches to assess chemokine levels in the
mammary gland, focusing on the 6.5 week time point. Many
chemokines were undetectable at this time point and others were
detectable but displayed no differences in protein levels between
wild-type and Ackr2−/− mammary glands (Fig. S2). In addition, no
differences in expression of the macrophage differentiation factor
CSF1 were seen (Fig. S2). However, elevated levels of CCL7,
CCL11 and CCL12 were seen in Ackr2−/− mammary glands
(Fig. 4A). Notably, qRT-PCR-based array analysis comparing the
transcriptional profiles of wild-type and Ackr2−/−mammary glands
in 6.5- (Fig. 4B) and 8-week-old mice (Fig. 4C) did not detect
differences in the transcript levels of these three chemokines
(Table S1). Thus, their elevated levels are a result of deficient
scavenging in Ackr2−/− mice and not increased transcription.
ACKR2 controls the accumulation of macrophages in the
mammary gland
The three chemokines identified as being increased at the protein
level in Ackr2−/− mammary glands are regulators of macrophage,
eosinophil and mast cell recruitment that act in differing
combinations through chemokine receptors CCR1, CCR2, CCR3
and CCR5 (White et al., 2013). Importantly, ACKR2 deficiency
does not appear to alter eosinophil or mast cell recruitment, both of
which are known to mediate effects on branching morphogenesis
(Gouon-Evans et al., 2000; Lilla and Werb, 2010) (Fig. S3). By
contrast, differences in macrophage dynamics were observed in
Ackr2−/−, compared with wild-type, mammary glands following
FACS analysis of enzymatically digested mammary gland cells
from pubertal and adult mice. There was no difference in the
percentage of CD45+ CD11b+ F4/80+ macrophages (Fig. 5A)
isolated fromwild-type and Ackr2−/− glands at 6 weeks; however, at
Fig. 3. ACKR2 is expressed by stromal cells in the mammary gland. (A) Relative levels of ACKR2 expression (2−ΔCT) during virgin mammary gland
development (n=3), pregnancy, lactation and involution (n=2). (B) Flow cytometry was used to determine the percentage of uptake of the fluorescent ACKR2
ligand CCL22 by (1) CD45+ and (2) CD45− wild-type and Ackr2−/− mammary gland cells. Results were combined from three individual experiments (wild type,
n=16; Ackr2−/−, n=14). (C) Alexa-CCL22 uptake by a stromal population of CD45−CD29+CD24−Sca1+CD90+ cells in wild-type and Ackr2−/−mice. Results were
combined from two individual experiments (wild type, n=10, Ackr2−/− n=10). (D) Representative FACS plots of Alexa-CCL22 uptake by
CD45−CD29+CD24−Sca1+CD90+ cells in wild-type and Ackr2−/− mice. Alexa-CCL22+ populations were gated using control cells without fluorescent CCL22
added. (E) Mean fluorescence intensity of Alexa-CCL22 indicates binding and uptake by CD45−, CD29+,CD24−Sca1+,CD90+ fibroblasts at 4°C and 37°C.
Results were combined from two individual experiments (wild type, n=10, Ackr2−/− n=10). Significantly different results are indicated. Error bars represent s.e.m.
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6.5 weeks the percentage of macrophages in Ackr2−/− glands was
significantly higher than in wild-type (Fig. 5B). By 8 weeks this
differential had reversed. In addition, Mac2-stained sections from
mice at 6.5 weeks indicated higher numbers of macrophages
associated with the TEBs in Ackr2−/− compared with wild-type
mice, whereas the reverse was observed at 8 weeks (Fig. 5C). This
was quantified (Fig. 5D), which confirmed the altered numbers of
TEB-associated macrophages in the Ackr2−/−micewere statistically
significant. Importantly, no differences were seen in the numbers of
macrophages in the adipose tissues surrounding the TEBs (Fig. 5E).
This accelerated recruitment of macrophages in Ackr2−/− mice is
consistent with the precocious developmental phenotype observed.
In adult 12-week-old mice there is no difference in the number of
macrophages, consistent with branching being unaffected at this
time point (Figs 2 and 5B).
CCR2 is not the sole regulator of macrophage recruitment
and dynamics in the developing mammary gland
In embryonic skin, ACKR2 regulates the gradient of the CCR2
ligand CCL2 to control macrophage proximity to the developing
lymphatic network; as such, Ccr2−/− mice have a reciprocal
phenotype to Ackr2−/− mice, including reduced lymphatic vessel
density (Lee et al., 2014). To determine whether mammary gland
branching morphogenesis is impaired in the absence of CCR2
during puberty, Carmine Alum whole-mount staining of age- and
weight-matched virgin wild-type and Ccr2−/− glands was carried
out. The number of branches, the branched area and the distance
between branches was unaffected by CCR2 deletion, indicating that
ACKR2 controls branching morphogenesis in the mammary gland
through a distinct mechanism that is independent of CCR2 (Fig. 6A,
Ba-c). There were also no differences in the numbers of TEBs, in
LN size or in ductal elongation in the Ccr2−/−mice (Fig. 6Bd-f ). Of
note, CCR2 does affect morphology, as the size of individual TEBs
are increased in Ccr2−/−mice at 6.5 weeks (Fig. S4A), and Ccr2−/−
branches are marginally thinner at 8 weeks (Fig. S4B). Our data
further indicate that Ccr2−/− mice display no differences in
macrophage, eosinophil or mast cell recruitment (Fig. S5).
These data therefore raise the issue of the identity of the
chemokine receptor(s) responsible for the exaggerated macrophage
recruitment in Ackr2−/− mammary glands. qRT-PCR analysis of
wild-type macrophages purified from the mammary gland at week 8
demonstrate that although these cells did not express ACKR2, they
simultaneously expressed CCR1, CCR2 and CCR5, and weakly
expressed CCR3 (Fig. 6C). It is therefore likely that these
macrophages are responsive to a range of chemokine receptor
ligands. Unfortunately, mouse models allowing an analysis of the
impact of compound receptor deficiency are not currently available
and thus the precise receptor use involved inmacrophage recruitment
to the developing mammary gland remains to be defined.
DISCUSSION
The importance of immune cells in mammary gland development is
well known (Gouon-Evans et al., 2000; Lilla and Werb, 2010);
however, the molecular cues guiding their migration into, and
positioning within, the gland are not well understood. Indeed,
relatively little is known about the roles of chemokines and their
receptors in normal mammary gland development. In this study we
have demonstrated that the atypical chemokine receptor ACKR2 is
expressed by a fibroblastic population of stromal cells and is a key
regulator of macrophage recruitment and positioning in the murine
Fig. 4. Chemokine levels in Ackr2−/−mammary glands. (A) Multiplex measurement of protein concentration of (a) CCL7; (b) CCL11 and (c) CCL12 in whole
mammary gland homogenates. n=8 per group. (B,C) Volcano plots of fold change versus significance between wild-type and Ackr2−/− glands at (B) 6.5 weeks
and (C) 8 weeks. Log2 fold change in gene expression between wild-type and Ackr2−/− mammary glands are plotted against t-test P values. Thresholds for
twofold change are indicated by vertical lines; significance (P<0.05) is indicated by a horizontal line; n=3 per group.
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mammary gland. Communication between the stroma and
epithelium is crucial, as the stroma provides a wealth of growth
factors, ECM proteins and microRNAs that tightly regulate ductal
elongation and patterning, the disruption of which often leads to
aberrant development (Kayo et al., 2014; Parmar and Cunha, 2004).
Here, we add a further example of crosstalk between the stroma and
epithelium, and the immunological signals that determine the
degree of branching and spacing between ducts.
Ackr2−/− mice exhibit rapid mammary gland development
throughout late puberty, which is characterised by increased
numbers of TEBs and branches, and is initiated by earlier
recruitment of macrophages to the mammary gland. Specifically,
the onset of accelerated development and macrophage recruitment
occurs at 6.5 weeks in Ackr2−/− mice, when ACKR2 expression
peaks in wild-type mice. This is associated with increased level of
macrophage chemoattractants in the Ackr2−/− mammary gland and
suggests that ACKR2 controls the temporal onset of mammary
gland development by regulating chemokine availability. Together,
our data indicate that 6.5 weeks is a key developmental time point at
which ACKR2 limits macrophage recruitment. Developmentally,
this coincides with the onset of sexual maturity (Topper and
Freeman, 1980). Overall, mammary gland development in Ackr2−/−
mice occurs ∼2 weeks earlier than in wild-type mice. Given that the
average lifespan of a mouse in the wild is approximately 6 months,
this represents a potentially important acceleration of this specific
aspect of sexual maturity.
Notably, postnatal control of macrophage recruitment by ACKR2
occurs through a distinct mechanism to that described in embryonic
skin, which is dependent on CCL2 and its receptor CCR2. In
contrast to embryonic skin, Ccr2−/− mice do not exhibit an inverse
phenotype in the mammary gland, as epithelial branching is not
affected. Furthermore, transcriptional analysis of pubertal mammary
glands revealed that CCL2 and CCR2 are unchanged in Ackr2−/−
mice. However, CCR2 does have effects on the morphology of the
ductal tree, with larger TEBs in pubertal mice and thinner branches
in adults. These effects are not caused by altered macrophage,
eosinophil or mast cell recruitment. qRT-PCR analysis of mammary
gland macrophages demonstrated expression of CCR1, CCR2 and
CCR5, as well as low level expression of CCR3. The known
complex and potentially redundant interactions between
inflammatory CC-chemokines and their receptors suggests that
these cells could use a variety of chemokines and cognate receptors
for migration into the mammary gland. The key chemokine
receptors occupy a tight chromosomal locus (Nomiyama et al.,
2011); therefore, compound chemokine receptor-null mice, which
would directly address this issue are not available at present, and
thus the precise receptors used by macrophages during recruitment
to the mammary gland await further characterisation. Notably, Fig. 4
shows increased transcription of the inflammatory chemokine
receptors CCR1 and CCR5 in Ackr2−/− mice at 6.5 weeks,
suggesting, again, that combinations of these receptors may be
involved in macrophage recruitment.
Here, we provide, for the first time, a comprehensive analysis of
chemokine transcription to gain broad insights into their roles
throughout the full course of virgin and reproductive development.
It has been shown that CCL11 (eotaxin)-mediated recruitment of
Fig. 5. ACKR2 controls the
accumulation of macrophages in the
mammary gland. (A) Flow cytometry
was used to identify the percentage of
CD11b+ F4/80+ macrophages within the
CD45+ population of the mammary gland
during development. Gating based on
fluorescence minus one (FMO) controls
is shown. (B) FACS analysis of wild-type
and Ackr2−/−-deficient glands was
carried out at 6, 6.5, 8 and 12 weeks.
Results were combined from two
independent experiments, n=8-11.
(C) Mac2+ cells, indicated by
arrowheads, were visualised within the
developing mammary gland by
immunohistochemistry. Representative
40× bright-field images of Mac2-stained
sections from wild-type and Ackr2−/−
glands are shown. (D,E) The number of
Mac2+ cells per gland was the average
counted from five individual FOV (40×)
either (D) around TEBs or (E) from within
adipose tissue, from 6 week (n=3),
6.5 week (n=5) and 8 week (wild type
n=5, KO n=4) glands. Significantly
different results are indicated. Error bars
represent s.e.m.
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eosinophils is required for proper TEB formation and ductal
elongation (Gouon-Evans et al., 2000). Here, we observed that
expression of CCL11 is highest in developing virgin and involuting
glands, suggesting recruitment of eosinophils is reduced during
pregnancy and lactation. In a previous study, CCL28 and CCR10
have been shown to facilitate the homing and accumulation of IgA
antibody-secreting cells during lactation (Morteau et al., 2008).
Consistent with this, we observed high levels of CCL28 during
lactation. In addition, CXCL1 has been previously reported to
comprise part of an involution-associated gene signature on day 1 of
involution, which is again identified in this study and suggests that
neutrophil influx is important during involution (Clarkson et al.,
2003; Reed and Schwertfeger, 2010; Stein et al., 2004). CXCL14
(BRAK) was initially identified in breast tissue and is expressed
here throughout mammary development, with the highest level
present during involution (Hromas et al., 1999). CXCR4 is known
to be expressed at low levels in normal breast tissue, but is
characteristic of malignant epithelial cell growth, and is important
for metastasis (Balkwill, 2004; Wiseman and Werb, 2002). In this
study, CXCR4 is strongly associated with pregnancy, which could
have implications for our understanding of pregnancy-associated
breast cancer risk. Similarly CXCL12, a ligand of both CXCR4 and
ACKR3, is associated with advanced breast cancer in humans, and
is expressed at high levels during puberty and pregnancy in our
study (Fridrichova et al., 2015) (data not shown). ACKR3 (CXCR7)
promotes breast cancer cell proliferation (Salazar et al., 2014) and is
upregulated here during lactation and involution (data not shown).
Understanding the molecular basis of mammary gland
development is crucial to help us understand how breast cancers
arise. Normal developmental processes which involve proliferation
of the epithelium have high tumorigenic potential, for example the
ability to reinitiate cellular proliferation throughout reproduction,
produce anti-apoptotic signals during lactation to prevent premature
involution, and to induce angiogenesis during frequent vasculature
remodelling. In addition, the highly proliferative nature of the TEB
and its ability to invade stromal tissues strongly resemble features of
some solid tumours (Wiseman andWerb, 2002). It is also important
to further understand how macrophages are regulated within the
mammary gland, as they are vital both for pubertal development and
metastatic tumour progression (Gouon-Evans et al., 2000; Lin et al.,
2001). Here, we describe an important role for ACKR2 in the
control of macrophages that potentiate epithelial branching during
normal breast development. This may provide insights into the
origin and development of tumours and potentially allow
therapeutic intervention.
MATERIALS AND METHODS
Animals
Animal experiments were carried out using female age-matched mice and
conformed to the animal care and welfare protocols approved by the
Fig. 6. CCR2 does not control branching morphogenesis within the developing mammary gland. (A) Representative Carmine Alum staining of wild-type
and Ccr2−/− mammary gland whole mounts at 6.5 and 8 weeks of age is shown. (B) Ccr2−/− stained whole mounts were quantified for: (a) the number of
branches; (b) the branched area; (c) the distance between branches; (d) the number of TEBs; (e) lymph node size; and (f ) ductal elongation (n=4). Each
measurement was from three FOV (5×) per gland. Wild-type data points are the same as those used in Fig. 2B. Results were not statistically significant.
(C) qRT-PCR analysis of expression of ACKR2, CCR1, CCR2, CCR3, CCR4 and CCR5 in sorted mammary gland macrophages. Error bars represent s.e.m.
80
RESEARCH ARTICLE Development (2017) 144, 74-82 doi:10.1242/dev.139733
D
E
V
E
LO
P
M
E
N
T
University of Glasgow and carried out under the auspices of a UK Home
Office Project Licence. C57BL/6 mice, Ackr2−/− mice (Jamieson et al.,
2005) and Ccr2−/− mice were bred in-house at the specific pathogen-free
facilities at the Beatson Institute for Cancer Research (Glasgow, UK).
Transcriptional analysis
To isolate RNA, the inguinal lymph node (LN) was removed and mammary
tissue from the fourth inguinal gland was minced coarsely with dissecting
scissors before being added to Qiazol with 7 mm stainless steel beads
(Qiagen). Samples were processed using a Tissuelyser LT for 10 min at a rate
of 50 s−1, and the miRNeasy kit as described in the manufacturer’s
instructions (Qiagen). RNA samples from reproductive stages were collected
during pregnancy, lactation and forced involution, as described previously
(Olijnyk et al., 2014; Stein et al., 2004). Purified mammary gland
macrophages were lysed in Buffer RLT and processed using a
QIAshredder (Qiagen) before using a microRNeasy kit (Qiagen) to isolate
RNA. From tissue samples, 400 ng RNAwas converted to cDNA using the
RT2 First Strand kit and 1-2 ng RNA from purified macrophage samples
were preamplified using the RT2 PreAMP cDNA Synthesis Kit and array-
specific primers (Qiagen). Transcription levels were determined by
quantitative real-time polymerase chain reaction (qRT-PCR) using the
mouse Chemokine and Chemokine Receptor RT2 profiler PCR array
(Qiagen) and RT2 SYBR Green ROX qPCR Mastermix (Qiagen), as
described in the manufacturer’s instructions. Fold regulation was determined
using the 2(−ΔCt) method, where ΔCT is calculated as CT target−CT normaliser.
Normalisation was carried out using the arithmetic mean of the CT of
GAPDH,Hsp90a and β-actin. Volcano plotswere used to identify significant
gene expression changes. Non-supervised hierarchical clusteringwas used to
show common gene expression and co-regulated genes across groups using
the SABiosciences data analysis software (Qiagen).
Whole-mount analyses
Fourth inguinal mammary glands were spread onto Superfrost Plus
microscope slides (Thermo Scientific) and fixed overnight in 10% neutral
buffered formalin (NBF) (Leica) at 4°C. Tissuewas dehydrated by incubation
for 1 h in distilled water, followed by 70% ethanol and 100% ethanol (VWR
international) before overnight incubation in xylene (VWR international) at
room temperature. Tissues were then rehydrated by subsequent 1 h
incubations in 100% ethanol, 70% ethanol and distilled water, and stained
in Carmine Alum solution [0.2% (w/v) carmine and 10 mM aluminium
potassium sulphate (Sigma)], overnight at room temperature. Tissue was
dehydrated again by 1 h incubations in distilledwater, 70%ethanol and100%
ethanol, and overnight incubation in xylene at room temperature. Finally,
glands were mounted using DPX (Leica) and stitched bright-field images at
10× magnification were obtained using the Evos Cell Imaging System
(Thermo Scientific). Ductal elongation, post-LN branched area and LN size
were measured using ImageJ 1.48v (Schneider et al., 2012). Bright-field
images (5×) were obtained using the Zeiss Axioimager M2 with Zen 2012
(blue edition) software. The numbers of branches and TEBs were counted as
the average from three individual fields of view (FOV) from each whole
mount. The average distance between branches and branch thickness was
calculated from three measurements from each of 3 individual FOV.
Immunocytochemical analyses
Fourth inguinal mammary glands were fixed in 10% NBF, treated using a
tissue processor (Thermo Scientific) and embedded in paraffin wax using an
embedding suite (Thermo Scientific). Sections were cut at 4-6 μm on a
microtome (Thermo Scientific), floated in a 40°C water bath (Thermo
Scientific) and collected onto Superfrost Plusmicroscope slides before being
baked at 60°C for 30 min. After treatmentwith xylene for 10 min, slideswere
rehydrated by 5 min incubations in 100% ethanol, 70% ethanol and running
water. After this, they were placed in distilled water and rinsed with PBS
(Sigma). H2O2 (3% ; Fisher Scientific) was applied for 5 min before being
rinsed again with PBS. Slides were blocked using a 20% goat serum (Vector
Labs) before staining overnight at 4°C with a 1 in 6000 dilution in PBS
containing 1%BSA (Sigma) of either primary rat anti-mouseMac2 antibody
(Cedarlane) or the isotype control antibody IgG2a (BD Biosciences). Slides
werewashed three times in PBS for 5 min before adding a 1 in 200 dilution of
goat anti-rat IgG (Vector Labs). Slides were washed in PBS and a 1 in 200
dilution of Extravadin-peroxidase (Sigma) was applied for 30 min before
being washed again. Diaminobenzidine (DAB) substrate (Vector Labs) was
applied and quenched with tap water. Finally, Haematoxylin was added as a
counterstain before being dehydrated in 70%, 90% and 100% ethanol and
xylene (VWR International), and mounted in DPX.
Mammary gland cell isolation
Inguinal lymph nodewas removed andmammary tissuewas coarselyminced
before enzymatic digestion with 3 mg/ml (w/v) collagenase type 1 (Sigma)
and 1.5 mg/ml (w/v) trypsin (Sigma) in serum-free Leibovitz L-15 medium
(Sigma) in a shaking incubator at 200 rpm (37°C for 45 min). The suspension
was shaken by hand for 15 s before addition of an equal volume of ice-cold
Leibovitz L-15medium supplementedwith 10% fetal calf serum (Invitrogen)
(L-15/10% FCS) and centrifugation for 5 min at 350 g. Supernatants were
gently aspirated and erythrocytes were lysed using Red Blood Cell Lysing
Buffer Hybri-Max (Sigma) for 1 min and washed in PBS. Cells were washed
again in PBS with 5 mM EDTA, resuspended in 2 ml 0.25% Trypsin-EDTA
(Sigma) and incubated at 37°C for 2 min before addition of 5 ml of serum-
free L15 containing 1 μg/ml DNase1 (Sigma) for 5 min at 37°C. An equal
volume of L-15/10% FCS was added to stop the reaction and cells were
filtered through a 40 μmcell strainer before a final wash in FACS buffer, PBS
containing 1% FCS and 5 mM EDTA. Mammary gland macrophages were
isolated using MACS LS columns (Miltenyi Biotec) by staining with F4/80
conjugated with APC and anti-APC microbeads.
Proteomic analysis
Mammary tissue without the inguinal lymph node was coarsely minced
before being frozen in liquid nitrogen, crushed with a mortar and pestle, and
resuspended in dH2O containing protease inhibitors (Pierce). Protein levels
were determined using a customised Magnetic Luminex Multiplex assay
(R&D Systems), as described in the manufacturers’ instructions, and read
using a Bio-Rad Luminex-100 machine. Protein concentration of tissue
samples was determined using the BCA assay (Pierce).
Flow cytometry
The following antibodies were obtained from BioLegend and used at a
dilution of 1:200: CD45 (30-F11), CD11c (N418), CD11b (M1/70), CD117
(2B8), CD24 (M1/69), CD29 (HMβ1-1) and CD90.2 (30-H12). F4/80
(BM8) from eBiosciences and Siglec F (E50-2440) from BD Biosciences
were used at a dilution of 1:200. Sca1 (D7) fromMiltenyi biotec was used at
a dilution of 1:50. Dead cells were excluded using DRAQ7 (BioStatus) or
Fixable Viability Dye eFluor 506 (ebioscience). Macrophages were defined
as CD11b+ F4/80+, eosinophils as CD11c− Siglec F+ and mast cells as
CD117+. Fluorescent chemokine uptake experiments were carried out using
0.5 μg AF647-labelled human CCL22 (Almac, Scotland UK) as described
previously (Ford et al., 2013). FACS was performed using an LSRII, (BD
Biosciences) and analysed using FlowJo V10.
Statistical analysis
Data were analysed using GraphPad Prism 5.03. F tests were carried out to
compare variances and normality was assessed using the Kolmogorov–
Smirnov test. Two-tailed, unpaired t-tests were used to analyse data with
normal distribution, Mann–Whitney or one-way ANOVA with Tukey’s
multiple comparison tests was applied for comparison of groups, as
appropriate. Significancewas indicated by *P<0.05. Error bars indicate s.e.m.
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